Details for New Drug Application (NDA): 213942
✉ Email this page to a colleague
The generic ingredient in BUMETANIDE is bumetanide. There are six drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the bumetanide profile page.
Summary for 213942
Tradename: | BUMETANIDE |
Applicant: | Rubicon |
Ingredient: | bumetanide |
Patents: | 0 |
Pharmacology for NDA: 213942
Physiological Effect | Increased Diuresis at Loop of Henle |
Medical Subject Heading (MeSH) Categories for 213942
Suppliers and Packaging for NDA: 213942
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
BUMETANIDE | bumetanide | TABLET;ORAL | 213942 | ANDA | Advagen Pharma Limited | 72888-019 | 72888-019-01 | 100 TABLET in 1 BOTTLE (72888-019-01) |
BUMETANIDE | bumetanide | TABLET;ORAL | 213942 | ANDA | Advagen Pharma Limited | 72888-020 | 72888-020-01 | 100 TABLET in 1 BOTTLE (72888-020-01) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 0.5MG | ||||
Approval Date: | Dec 27, 2024 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 1MG | ||||
Approval Date: | Dec 27, 2024 | TE: | AB | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 2MG | ||||
Approval Date: | Dec 27, 2024 | TE: | AB | RLD: | No |
Complete Access Available with Subscription